US · AGEN · BIOTECHNOLOGY
Agenus Inc. (AGEN) intrinsic value and stock valuation
$5.97as of 2026-11-21 · Mkt cap 289.83M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Agenus Inc. DCF and intrinsic value
InvestorsCraft values AGEN with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from AGEN’s statements →
Agenus Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $114.2M | $103.5M | $156.3M | $98M | $295.7M |
| Operating income | -$-20.56M | -$-120.47M | -$-159.55M | -$-179.43M | $25.8M |
| Net income | $120K | -$-227.21M | -$-245.76M | -$-220.07M | -$-23.93M |
| EPSd | $4.04K | -$-10.58M | -$-13.74M | -$-15.62M | -$-2.09M |
| Operating cash flow | -$-158.31M | -$-158.31M | -$-224.2M | -$-175.37M | $10.1M |
| Capital expenditure | -$-580K | -$-580K | -$-9.95M | -$-53.06M | -$-33.81M |
| Free cash flow | -$-158.89M | -$-158.89M | -$-234.16M | -$-228.44M | -$-23.67M |
| Total assets | $226.8M | $226.3M | $313.9M | $413.6M | $466M |
| Total debt | $334.9M | $94.9M | $93.2M | $78.4M | $58.3M |
| Net debt | $331.9M | $54.4M | $17.1M | -$-100.25M | -$-233.64M |
| Total equity | -$-277.86M | -$-306.42M | -$-148.38M | -$-54.9M | $47.9M |
| Cash and short-term investments | $3M | $40.4M | $76.1M | $193.4M | $306.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $114.2M | $103.5M | $156.3M | $98M | $295.7M |
| Cost of revenue | $80.4M | $156M | $237.7M | $197.3M | $182.1M |
| Gross profit | $33.8M | -$-52.55M | -$-81.37M | -$-99.23M | $113.6M |
| Research and development expenses | $0.00 | $155.5M | $234.6M | $0.00 | $178.6M |
| Selling, general and administrative expenses | $54.4M | $71.9M | $78.7M | $81M | $76.4M |
| Other expenses | $0.00 | -$-159.48M | -$-235.12M | -$-810K | -$-167.13M |
| Operating expenses | $54.4M | $67.9M | $78.2M | $80.2M | $87.8M |
| Cost and expenses | $134.8M | $223.9M | $315.9M | $277.5M | $269.9M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $55.3M | $117.6M | $97.9M | $61.9M | $65.7M |
| Depreciation and amortization | $10M | $13.3M | $13.6M | $6.95M | $6.79M |
| Ebitda | $62.2M | -$-101.3M | -$-145.92M | -$-161.85M | $43.8M |
| Operating income | -$-20.56M | -$-120.47M | -$-159.55M | -$-179.43M | $25.8M |
| Total other income/expenses, net | $17.5M | -$-111.8M | -$-97.89M | -$-51.23M | -$-54.47M |
| Income before tax | -$-3.08M | -$-232.27M | -$-257.44M | -$-230.66M | -$-28.72M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $120K | -$-227.21M | -$-245.76M | -$-220.07M | -$-23.93M |
| Weighted average shares outstanding | $29.7M | $21.5M | $17.9M | $14.1M | $11.5M |
| Weighted average diluted shares outstanding | $29.7M | $21.5M | $17.9M | $14.1M | $11.5M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $3M | $40.4M | $76.1M | $193.4M | $306.9M |
| Net receivables | $1.83M | $410K | $25.8M | $2.74M | $1.52M |
| Inventory | $0.00 | $0.00 | $0.00 | $13.8M | $20.4M |
| Total current assets | $133.4M | $45.6M | $112.4M | $213.1M | $332M |
| Property, plant and equipment, net | $24.3M | $147.4M | $163M | $164.3M | $91.1M |
| Goodwill and intangible assets | $27.1M | $27.5M | $29.1M | $31.7M | $33.4M |
| Long-term investments | $42.7M | $4.64M | $3.22M | $0.00 | $0.00 |
| Total non-current assets | $93.4M | $180.7M | $201.5M | $200.4M | $134M |
| Total assets | $226.8M | $226.3M | $313.9M | $413.6M | $466M |
| Accounts payable | $83M | $61.5M | $61.5M | $40.9M | $30.5M |
| Short-term debt | $156.3M | $9.85M | $13.2M | $2.52M | $3.35M |
| Deferred revenue | $1.14M | $30K | $20K | $12.3M | $12.4M |
| Total current liabilities | $323.5M | $221.4M | $255.9M | $189M | $156.9M |
| Long-term debt | $179.8M | $85M | $80M | $75.9M | $54.9M |
| Deferred revenue, non-current | $1.14M | $1.14M | $1.14M | $1.14M | $11.2M |
| Total non-current liabilities | $181.2M | $311.3M | $206.4M | $279.5M | $261.1M |
| Capital lease obligations | $11.3M | $61.7M | $80.3M | $65.3M | $44.7M |
| Total liabilities | $504.7M | $532.7M | $462.3M | $468.5M | $418.1M |
| Common stock | $350K | $240K | $3.94M | $3.06M | $2.57M |
| Retained earnings | -$-2.18B | -$-2.18B | -$-1.96B | -$-1.71B | -$-1.49B |
| Accumulated other comprehensive income (loss) | -$-440K | -$-1.4M | -$-950K | $920K | $1.49M |
| Total equity | -$-277.86M | -$-306.42M | -$-148.38M | -$-54.9M | $47.9M |
| Total investments | $42.7M | $4.64M | $3.22M | $14.7M | $15M |
| Total debt | $334.9M | $94.9M | $93.2M | $78.4M | $58.3M |
| Net debt | $331.9M | $54.4M | $17.1M | -$-100.25M | -$-233.64M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-232.27M | -$-232.27M | -$-257.44M | -$-230.66M | -$-28.72M |
| Depreciation and amortization | $13.3M | $13.3M | $13.6M | $6.95M | $6.79M |
| Stock-based compensation | $17.4M | $17.4M | $22.9M | $18.3M | $19.6M |
| Change in working capital | $27.3M | $32.6M | $10.8M | $24.1M | -$-9.74M |
| Accounts receivable | -$-1.73M | $25.3M | -$-23.46M | $120K | -$-390K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $23.5M | $2.01M | $21.4M | $6.49M | $10.8M |
| Net cash provided by operating activities | -$-158.31M | -$-158.31M | -$-224.2M | -$-175.37M | $10.1M |
| Investments in property, plant and equipment | -$-580K | -$-580K | -$-9.95M | -$-53.06M | -$-33.81M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-2.92M | $0.00 |
| Net cash used for investing activities | $30K | $30K | $3.4M | -$-33.61M | -$-43.15M |
| Common stock issued | $36.3M | $38.8M | $133.2M | $99.2M | $220.7M |
| Common stock repurchased | -$-90K | $0.00 | -$-5.17M | -$-3.79M | -$-1.65M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $122.8M | $122.8M | $119.9M | $95.8M | $225.3M |
| Net change in cash | -$-35.71M | -$-35.71M | -$-101.56M | -$-113.26M | $192.1M |
| Cash at end of period | $44.1M | $44.1M | $79.8M | $181.3M | $294.6M |
| Operating cash flow | -$-158.31M | -$-158.31M | -$-224.2M | -$-175.37M | $10.1M |
| Capital expenditure | -$-580K | -$-580K | -$-9.95M | -$-53.06M | -$-33.81M |
| Free cash flow | -$-158.89M | -$-158.89M | -$-234.16M | -$-228.44M | -$-23.67M |
Line items
Line items
Line items
About Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.
- CEO
- Garo H. Armen
- Employees
- 81
- Beta
- 1.55
Explore
Frequently asked questions
What is the intrinsic value of Agenus Inc. (AGEN)?
Agenus Inc. (AGEN) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is AGEN undervalued?
AGEN trades at a price of $5.97 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.